The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
NCT ID: NCT04308343
Last Updated: 2020-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2020-03-30
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Use of the aromatase inhibitor( letrozole) for the treatment of ectopic pregnancy compared to methotrexate.
2. Use of the Gnrh antagonist for the treatment of ectopic pregnancy compared to methotrexate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Letrozole for Ectopic Pregnancy
NCT06354439
Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy
NCT05918718
Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole + Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy
NCT06504082
Letrozole in Tubal Ectopic Pregnancy
NCT04341545
Monotherapy With Letrozole in Tubal Pregnancy
NCT05839561
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methotrexate group
Methotrexate
Drugs to treat undisturbed ectopic pregnancies
Letrozole group
Letrozole
Drugs to treat undisturbed ectopic pregnancies
Gonadotropins releasing hormone antagonist group
cetrotide
Drugs to treat undisturbed ectopic pregnancies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methotrexate
Drugs to treat undisturbed ectopic pregnancies
Letrozole
Drugs to treat undisturbed ectopic pregnancies
cetrotide
Drugs to treat undisturbed ectopic pregnancies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. have no significant pain
2. have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35mm with no visible heartbeat
3. have a serum human chorionic gonadotropins level less than 1,500 IU/litre
4. do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) .
Exclusion Criteria
2. An undisturbed ectopic pregnancy with an adnexal mass of 35 mm or larger
3. An undisturbed ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan
4. An undisturbed ectopic pregnancy and a serum human chorionic gonadotropins level of 5,000 IU/litre or more
5. intrauterine pregnancy
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ali saber ali
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Aromatase inhibitor in ectopic
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.